Navamedic ASA - Mandatory notification of trade by primary insider

Oslo, 9 September 2024: Reference is made to the stock exchange announcement published earlier today, on 9 September 2024 by Navamedic ASA (the "Company" or "Navamedic"), regarding the board of directors' resolution to increase the Company's share capital with NOK 170,200 by the issuance of 230,000 new shares, in order to facilitate the settlement of exercise of 230,000 share options in the Company. The following primary insiders have today exercised share options: Kathrine Gamborg Andreassen, CEO of Navamedic, has today, on September 9 2024, exercised 80,000 share options in the Company under her option agreement from 2020 and subscribed for 80,000 new shares in the Company. Following the option exercise and subscription of the new shares, Kathrine Gamborg Andreassen holds 771,668 shares and 200,000 options in the Company. Ole Henrik Eriksen, CBDO of Navamedic, has today, on September 9 2024, exercised 75,000 share options in the Company under his option agreement from 2020 and subscribed for 75,000 new shares in the Company. Following the option exercise and subscription of the new shares, Ole Henrik Eriksen holds 575,000 shares and 200,000 options in the Company. Alexander Lidmejer, Commercial Director of Navamedic, has today, on September 9 2024, exercised 75,000 share options in the Company under his option agreement from 2020 and subscribed for 75,000 new shares in the Company. Following the option exercise and subscription of the new shares, Alexander Lidmejer holds 77,400 shares and 200,000 options in the Company. Please refer to the attached notification of trading for further details. This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.